Catalyst Pharmaceuticals Form 4 / PATRICK J MCENANY ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

MCENANY PATRICK J

(Last)

(First)

(Middle)

355 ALHAMBRA CIRCLE, SUITE 801

(Street)

CORAL GABLES

33134

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
CATALYST PHARMACEUTICALS, INC. [ CPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
Chairman of Board of Directors

3. Date of Earliest Transaction (Month/Day/Year)
11/11/2024

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock, par value $0.001 per share	11/11/2024		M		230,000	A	$4.01	4,708,169	D
Common stock, par value $0.001 per share	11/11/2024		S		230,000⁽¹⁾	D	$23.548⁽²⁾	4,478,169	D
Common stock, par value $0.001 per share	11/12/2024		M		70,000	A	$4.01	4,548,169	D
Common stock, par value $0.001 per share	11/12/2024		S		70,000⁽¹⁾	D	$23.421⁽³⁾	4,478,169	D
Common stock, par value $0.001 per share	11/12/2024		M		192,000	A	$3.54	4,670,169	D
Common stock, par value $0.001 per share	11/12/2024		S		192,000⁽¹⁾	D	$23.201⁽⁴⁾	4,478,169	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Options to purchase common stock	$4.01	11/11/2024		M			230,000	⁽⁵⁾	01/02/2025	Common Stock	230,000	$0	2,362,745	D
Options to purchase common stock	$4.01	11/12/2024		M			70,000	⁽⁵⁾	01/02/2025	Common Stock	70,000	$0	2,292,745	D
Options to purchase common stock	$3.54	11/12/2024		M			192,000	⁽⁶⁾	05/29/2025	Common Stock	192,000	$0	2,100,745	D

Explanation of Responses:

1. Shares were sold for personal reasons, including paying federal income taxes and diversifying the Reporting Person's portfolio. Shares were not sold as a result of any disagreement with the Company. Mr. McEnany remains the non-executive chairman of the Company's Board of Directors and the Company's largest individual, non-institutional shareholder.

2. Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.29 to $23.873 per share.

3. Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.30 to $23.50 per share.

4. Represents a weighted average price for the shares sold. Shares were sold in various lots ranging from $23.03 to $23.48 per share.

5. Options vested in three equal tranches on January 2, 2019, 2020 and 2021.

6. Options vested in three equal tranches on May 29, 2019, 2020 and 2021.

	/s/ Patrick J. McEnany	11/13/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Catalyst Pharmaceuticals (CPRX) Form 4CATALYST PHARMACEUTICALS / PATRICK J MCENANY ownership change